tetano
Editor, Senior Moderator
J Cell Physiol. 2019 Feb 19. doi: 10.1002/jcp.28339. [Epub ahead of print]
[h=1]Induction of protective immune response to intranasal administration of influenza virus-like particles in a mouse model.[/h] Keshavarz M[SUP]1,[/SUP][SUP]2[/SUP], Namdari H[SUP]3[/SUP], Arjeini Y[SUP]4[/SUP], Mirzaei H[SUP]5[/SUP], Salimi V[SUP]4[/SUP], Sadeghi A[SUP]6[/SUP], Mokhtari-Azad T[SUP]4,[/SUP][SUP]7[/SUP], Rezaei F[SUP]4,[/SUP][SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Human influenza A viruses (IAVs) cause global pandemics and epidemics, which remains a nonignorable serious concern for public health worldwide. To combat the surge of viral outbreaks, new treatments are urgently needed. Here, we design a new vaccine based on virus-like particles (VLPs) and show how intranasal administration of this vaccine triggers protective immunity, which can be exploited for the development of new therapies. H1N1 VLPs were produced in baculovirus vectors and were injected into BALB/c mice by the intramuscular (IM) or intranasal (IN) route. We found that there were significantly higher inflammatory cell and lymphocyte concentrations in bronchoalveolar lavage samples and the lungs of IN immunized mice; however, the IM group had little signs of inflammatory responses. On the basis of our results, immunization with H1N1 influenza VLP elicited a strong T cell immunity in BALB/c mice. Despite T cell immunity amplification after both IN and IM vaccination methods in mice, IN-induced T cell responses were significantly more intense than IM-induced responses, and this was likely related to an increased number of both CD11b[SUP]high[/SUP] and CD103[SUP]+[/SUP] dendritic cells in mice lungs after IN administration of VLP. Furthermore, evaluation of interleukin-4 and interferon gamma cytokines along with several chemokine receptors showed that VLP vaccination via IN and IM routes leads to a greater CD4[SUP]+[/SUP] Th1 and Th2 response, respectively. Our findings indicated that VLPs represent a potential strategy for the development of an effective influenza vaccine; however, employing relevant routes for vaccination can be another important part of the universal influenza vaccine puzzle.
? 2019 Wiley Periodicals, Inc.
[h=4]KEYWORDS:[/h] immunization; influenza A virus; therapy; virus-like particle (VLP)
PMID: 30784082 DOI: 10.1002/jcp.28339
[h=1]Induction of protective immune response to intranasal administration of influenza virus-like particles in a mouse model.[/h] Keshavarz M[SUP]1,[/SUP][SUP]2[/SUP], Namdari H[SUP]3[/SUP], Arjeini Y[SUP]4[/SUP], Mirzaei H[SUP]5[/SUP], Salimi V[SUP]4[/SUP], Sadeghi A[SUP]6[/SUP], Mokhtari-Azad T[SUP]4,[/SUP][SUP]7[/SUP], Rezaei F[SUP]4,[/SUP][SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Human influenza A viruses (IAVs) cause global pandemics and epidemics, which remains a nonignorable serious concern for public health worldwide. To combat the surge of viral outbreaks, new treatments are urgently needed. Here, we design a new vaccine based on virus-like particles (VLPs) and show how intranasal administration of this vaccine triggers protective immunity, which can be exploited for the development of new therapies. H1N1 VLPs were produced in baculovirus vectors and were injected into BALB/c mice by the intramuscular (IM) or intranasal (IN) route. We found that there were significantly higher inflammatory cell and lymphocyte concentrations in bronchoalveolar lavage samples and the lungs of IN immunized mice; however, the IM group had little signs of inflammatory responses. On the basis of our results, immunization with H1N1 influenza VLP elicited a strong T cell immunity in BALB/c mice. Despite T cell immunity amplification after both IN and IM vaccination methods in mice, IN-induced T cell responses were significantly more intense than IM-induced responses, and this was likely related to an increased number of both CD11b[SUP]high[/SUP] and CD103[SUP]+[/SUP] dendritic cells in mice lungs after IN administration of VLP. Furthermore, evaluation of interleukin-4 and interferon gamma cytokines along with several chemokine receptors showed that VLP vaccination via IN and IM routes leads to a greater CD4[SUP]+[/SUP] Th1 and Th2 response, respectively. Our findings indicated that VLPs represent a potential strategy for the development of an effective influenza vaccine; however, employing relevant routes for vaccination can be another important part of the universal influenza vaccine puzzle.
? 2019 Wiley Periodicals, Inc.
[h=4]KEYWORDS:[/h] immunization; influenza A virus; therapy; virus-like particle (VLP)
PMID: 30784082 DOI: 10.1002/jcp.28339